If a compounded product contains peptide fragments, impurities, aggregates, degradation products, or an incompletely characterised active ingredient, the immune system may recognise parts of that product as foreign
Consequently, although obesity affects hundreds of millions of people globally, GLP-1 therapies currently reach only a small fraction of eligible patients, underscoring the substantial unmet need for more convenient, scalable, and accessible treatment options
Rifaximin is the most extensively studied SIBO antibiotic and is preferred for its minimal absorption, fewer systemic side effects, and sustained efficacy, especially in patients with IBS and SIBO
[DOI] [PMC free article] [PubMed] [Google Scholar] 86.Kim S, et al